Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors
- PMID: 15632381
- DOI: 10.1093/jnci/dji002
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors
Abstract
Background: Whether bone markers have prognostic value in patients with bone metastases is unknown. We investigated this question in patients with bone metastases secondary to prostate cancer and to non-small-cell lung cancer (NSCLC) and other solid tumors assigned to the placebo arms of two phase III trials of zoledronic acid.
Methods: Levels of the urinary bone resorption marker N-telopeptide and the serum bone formation marker bone-specific alkaline phosphatase were assessed every 3 months for patients with prostate cancer (n = 203) or NSCLC or other solid tumors (n = 238) and were categorized as low or high. Patients were monitored for skeletal-related events, bone disease progression, and death. The relative risks (RRs) and 95% confidence intervals (CIs) for these outcomes were estimated for patients with high versus low levels of each marker using intensity-based multiple event and Cox regression models. All statistical tests were two-sided.
Results: In each disease group and overall, high levels of each marker at the beginning of the study were statistically significantly associated with an increased risk of negative outcomes. Use of recent marker assessments as time-dependent covariates gave even greater prognostic significance. High N-telopeptide levels were a stronger prognostic indicator of negative outcomes than bone-specific alkaline phosphatase levels. In recent assessments, patients with high N-telopeptide levels had an increased relative risk of skeletal-related events (prostate cancer, RR = 3.25, 95% CI = 2.26 to 4.68, P<.001; NSCLC and other solid tumors, RR = 1.79, 95% CI = 1.15 to 2.79, P = .010), disease progression (prostate cancer, RR = 2.02, 95% CI = 1.48 to 2.74, P<.001; NSCLC and other solid tumors, RR = 1.91, 95% CI = 1.16 to 3.15, P = .011), and death (prostate cancer, RR = 4.59, 95% CI = 2.82 to 7.46, P<.001; NSCLC and other solid tumors, RR = 2.67, 95% CI = 1.85 to 3.85, P<.001) compared with patients with low N-telopeptide levels.
Conclusions: Baseline and recent bone marker levels were predictive of negative clinical outcomes in patients with bone metastases secondary to prostate cancer and to NSCLC and other solid tumors. N-telopeptide levels were more consistent prognostic indicators than bone-specific alkaline phosphatase for all tumor types, reflecting the key role of osteolysis in the development of skeletal complications.
Similar articles
-
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.J Clin Oncol. 2005 Aug 1;23(22):4925-35. doi: 10.1200/JCO.2005.06.091. Epub 2005 Jun 27. J Clin Oncol. 2005. PMID: 15983391
-
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.J Clin Oncol. 2003 Aug 15;21(16):3150-7. doi: 10.1200/JCO.2003.04.105. J Clin Oncol. 2003. PMID: 12915606 Clinical Trial.
-
Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.Anticancer Res. 2005 Mar-Apr;25(2B):1457-63. Anticancer Res. 2005. PMID: 15865105 Clinical Trial.
-
Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6397S-403S. doi: 10.1158/1078-0432.CCR-040030. Clin Cancer Res. 2004. PMID: 15448038 Review.
-
The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer.Curr Opin Oncol. 2008 Mar;20(2):155-61. doi: 10.1097/CCO.0b013e3282f54cf2. Curr Opin Oncol. 2008. PMID: 18300765 Review.
Cited by
-
Does clinical T1N0 GGN really require checking for distant metastasis during initial staging for lung cancer?Cancer Imaging. 2024 Jun 3;24(1):69. doi: 10.1186/s40644-024-00714-7. Cancer Imaging. 2024. PMID: 38831467 Free PMC article.
-
Intersecting Paths: Unraveling the Complex Journey of Cancer to Bone Metastasis.Biomedicines. 2024 May 13;12(5):1075. doi: 10.3390/biomedicines12051075. Biomedicines. 2024. PMID: 38791037 Free PMC article. Review.
-
Mechanism of regulating macrophages/osteoclasts in attenuating wear particle-induced aseptic osteolysis.Front Immunol. 2023 Oct 4;14:1274679. doi: 10.3389/fimmu.2023.1274679. eCollection 2023. Front Immunol. 2023. PMID: 37860014 Free PMC article. Review.
-
N-telopeptide as a potential diagnostic and prognostic marker for bone metastasis in human cancers: A meta-analysis.Heliyon. 2023 May 1;9(5):e15980. doi: 10.1016/j.heliyon.2023.e15980. eCollection 2023 May. Heliyon. 2023. PMID: 37215848 Free PMC article. Review.
-
Computed tomography density changes of bone metastases after concomitant denosumab.Skeletal Radiol. 2023 Aug;52(8):1567-1575. doi: 10.1007/s00256-023-04326-3. Epub 2023 Mar 24. Skeletal Radiol. 2023. PMID: 36961572
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical